CLINICAL TRIALS PROFILE FOR TRIUMEQ PD

All Clinical Trials for TRIUMEQ PD

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02342769 ↗	Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany	Completed	GlaxoSmithKline		2015-02-19	TRIUMPH is a prospective, non-interventional observational study on the use of the fixdose combination TRIUMEQ (Dolutegravir/Abacavir/Lamivudine) and the respective monitoring measures in the practice of HIV care in Germany. The primary study objective is a descriptive report of the incidence of therapeutic monitoring measures in HIV-infected patients under TRIUMEQ therapy in everyday routine practice in Germany. The study is designed to enroll approximately 400 patients. There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 3 years or until premature discontinuation (i.e., discontinuation of TRIUMEQ, due to death, withdrawal of consent, lost to follow-up. TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies.
NCT02342769 ↗	Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany	Completed	ViiV Healthcare		2015-02-19	TRIUMPH is a prospective, non-interventional observational study on the use of the fixdose combination TRIUMEQ (Dolutegravir/Abacavir/Lamivudine) and the respective monitoring measures in the practice of HIV care in Germany. The primary study objective is a descriptive report of the incidence of therapeutic monitoring measures in HIV-infected patients under TRIUMEQ therapy in everyday routine practice in Germany. The study is designed to enroll approximately 400 patients. There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 3 years or until premature discontinuation (i.e., discontinuation of TRIUMEQ, due to death, withdrawal of consent, lost to follow-up. TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies.
NCT02354053 ↗	Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations	Completed	CIHR Canadian HIV Trials Network	Phase 4	2015-11-01	Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.
NCT02354053 ↗	Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations	Completed	ViiV Healthcare	Phase 4	2015-11-01	Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.
NCT02354053 ↗	Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations	Completed	McGill University Health Center	Phase 4	2015-11-01	Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.
NCT02354053 ↗	Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations	Completed	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4	2015-11-01	Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.
NCT02509195 ↗	SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over	Completed	ViiV Healthcare	Phase 4	2015-08-04	The purpose of this study is to identify the effects that ageing may have on the drug levels, the safety and the efficacy of Dolutegravir. These effects will be measured in people who are aged 60 or over and taking antiretroviral therapy for HIV infection. Dolutegravir is a newly licenced anti HIV medication, which belongs to a class of drugs called Integrase Inhibitors. It is taken with two other wellknown agents, Abacavir and Lamivudine, as part of a one tablet once a day regimen, called Triumeq. There is little data available on Dolutegravir in the context of older age. The HIV population is ageing and the investigators know that older age can significantly change the effects and side effects of medications, including that of antiretrovirals. The investigators aim to investigate the treatment outcomes in older people taking Dolutegravir including the tolerability, efficacy and safety of the drug. The study will also assess the quality of life (wellbeing of individuals) and cognition (mental abilities) of people aged 60 or over, taking Dolutegravir. The results from this study may inform treatment choices and monitoring in this population in the future. The duration of involvement in the study will be 6 months with an additional screening visit and a checkup visit 10 days after end of study visit.

Clinical Trial Conditions for TRIUMEQ PD

Condition Name

Condition Name for TRIUMEQ PD
Intervention	Trials
HIV Infections	6
HIV	4
Amyotrophic Lateral Sclerosis	3
HIV-1-infection	3

Condition MeSH

Condition MeSH for TRIUMEQ PD
Intervention	Trials
HIV Infections	9
Acquired Immunodeficiency Syndrome	4
Immunologic Deficiency Syndromes	4
Amyotrophic Lateral Sclerosis	3

Clinical Trial Locations for TRIUMEQ PD

Trials by Country

Trials by Country for TRIUMEQ PD
Location	Trials
Australia	14
United States	12
Germany	8
Thailand	3
South Africa	2

Trials by US State

Trials by US State for TRIUMEQ PD
Location	Trials
Texas	2
California	2
Florida	2
Tennessee	1
Illinois	1

Clinical Trial Progress for TRIUMEQ PD

Clinical Trial Phase

Clinical Trial Phase for TRIUMEQ PD
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	6
Phase 3	3

Clinical Trial Status

Clinical Trial Status for TRIUMEQ PD
Clinical Trial Phase	Trials
Completed	10
Recruiting	3
Terminated	3

Clinical Trial Sponsors for TRIUMEQ PD

Sponsor Name

Sponsor Name for TRIUMEQ PD
Sponsor	Trials
ViiV Healthcare	11
Macquarie University, Australia	3
GlaxoSmithKline	2

Sponsor Type

Sponsor Type for TRIUMEQ PD
Sponsor	Trials
Other	30
Industry	16
NIH	5

Last updated: July 28, 2026

Triumeq PD clinical trials update, market analysis and exclusivity outlook: What to know for business planning

Triumeq PD is the pediatric “PD” formulation of Triumeq (dolutegravir/abacavir/lamivudine, DTG/ABC/3TC) aimed at dosing convenience and weight-band administration for children with HIV. As of the latest publicly available sources, the pediatric development track for Triumeq PD is the critical path item for timelines, while commercial uptake will hinge on FDA pediatric labeling, availability through pediatric channels, and payer adoption versus existing pediatric DTG regimens.

What is Triumeq PD and how does it differ from adult Triumeq?

Triumeq PD is a pediatric dosage form of dolutegravir plus abacavir and lamivudine. The “PD” designation in market and regulatory materials is used to distinguish the pediatric formulation and presentation from the standard adult Triumeq tablet.

Key differentiators used in commercial positioning

• Pediatric dosing approach: designed for weight-band administration rather than adult-style fixed dosing.
• Formulation intent: improve dosing flexibility for children, particularly where tablet swallowing is impractical.
• Labeling objective: pediatric indication expansion (age-based) and pediatric dosing instructions.

What clinical trials support Triumeq PD and what is the latest update?

A current, decision-grade clinical update requires trial-level endpoints and status (active, recruiting, completed), plus a date-stamped source. No such consolidated, date-specific trial status for “Triumeq PD” can be produced from the information available in this chat, so a complete clinical trials update cannot be compiled here.

How large is the addressable pediatric HIV market for Triumeq PD?

The market for pediatric antiretroviral therapy is driven by:

• Birth-to-adolescence HIV prevalence and treatment coverage.
• Scale-up of early infant diagnosis and treatment initiation.
• Pediatric regimen changes toward integrase inhibitors (including dolutegravir) where guideline pathways support them.

Commercial demand drivers

• Weight-band regimen suitability lowers dosing friction for clinics.
• Once-daily regimens support adherence and simplification compared with older multi-dose schedules.
• Dolutegravir adoption has shifted many pediatric pathways toward DTG-containing backbones.

What is the competitive landscape for pediatric DTG-based HIV regimens?

Triumeq PD competes indirectly with:

• Other pediatric DTG-containing fixed-dose combinations and co-packaged backbones.
• Existing pediatric NRTI backbones (ABC/3TC or alternatives) combined with DTG in locally available formulations.
• Pediatric formulations from multi-drug HIV vendors that already have procurement relationships with pediatric formularies.

Where substitution risk tends to concentrate

• Formularies and procurement tend to prefer regimens with entrenched availability and established pediatric dosing ease.
• Competing products that offer more straightforward weight-band dosing or better supply continuity can displace entrants even with similar clinical profiles.

When does Triumeq lose exclusivity, and what does that mean for Triumeq PD?

An exclusivity and patent-expiration timeline is the single largest determinant of generic and biosimilar risk for a small-molecule antiretroviral family. A complete exclusivity analysis for Triumeq PD requires Orange Book listings (drug substance and formulation), patent numbers, and expiration dates tied to the pediatric product. No Orange Book-derived dataset is available in this chat, so an accurate “when does Triumeq lose exclusivity” answer cannot be produced.

What patents protect Triumeq PD formulations and dosing?

Patent protection for Triumeq PD would typically include:

• Composition-of-matter for the active ingredients (dolutegravir, abacavir, lamivudine) where not already long expired.
• Formulation patents covering pediatric dosage forms, excipients, particle size, dissolution profiles, stability, or dosing uniformity.
• Method-of-use patents for pediatric dosing or weight-band regimens, if pursued.

A complete patent map for Triumeq PD requires specific published patent numbers, assignees, filing dates, and jurisdictional families. No such patent dataset is available here, so a data-complete “how many patents cover Triumeq PD” response cannot be generated.

What is the Orange Book status of Triumeq PD?

Orange Book status depends on specific NDA/BLA entries and the listed active ingredient + dosage form combinations. This chat does not provide the NDA number or Orange Book listing details required for an accurate status report, including:

• Patent list entries (listed patents by submission type)
• Expiration dates
• Exclusivity codes (if applicable)
• Suitability for generic paragraph IV strategy

Are there Paragraph IV ANDA challenges for Triumeq PD?

ANDA paragraph IV filings and outcomes drive generic entry risk, settlement leverage, and forecast timing. No information on paragraph IV challenges tied to the Triumeq PD-specific dosage form is present here, so a litigation-style answer cannot be generated.

What generic entry risks exist for Triumeq PD and when could generics launch?

Generic launch risk for a pediatric fixed-dose combination is shaped by:

• Whether the generic can avoid formulation-specific patents.
• Whether the generic formulation is considered “bioequivalent” with pediatric dosing acceptability.
• Whether the pediatric label is carved out or remains protected by method-of-use and formulation patents.
• Pediatric exclusivity extensions tied to pediatric studies (if any).

Without patent-expiration and exclusivity details for the Triumeq PD product entry, any launch timing estimate would be speculative.

What litigation affects Triumeq PD and what are the latest case milestones?

A litigation update requires case dockets or court filings linked to the specific Triumeq PD product family. No case-level information is available in this chat, so a court-milestones section cannot be produced.

How does Triumeq PD compare with alternative pediatric HIV options on formulation and access?

For pediatric HIV, product advantage often comes from:

• Fixed-dose simplicity.
• Weight-band dosing practicality.
• Stability, palatability, and dosing device compatibility.
• Supply continuity and ease of procurement.

A fully evidenced comparison requires product-specific data (dosage strengths, pediatric weight-band mapping, administration guidance, and availability) that is not provided here.

Regulatory outlook: what FDA milestones matter for Triumeq PD?

For a pediatric antiretroviral development program, the decision points typically include:

• FDA labeling finalization (age/weight indications, dosing instructions).
• Pediatric study completion submissions and any required supplements.
• Scheduling and REMS-type constraints if applicable (rare for small-molecule antiretrovirals compared with some other therapeutic classes).

No Triumeq PD-specific FDA milestone timeline is available in the current input, so a date-accurate regulatory outlook cannot be produced.

Market projection for Triumeq PD: what trajectory should investors and planners expect?

A market projection needs at least:

• Current pediatric utilization baseline.
• Labeling timing and competitive substitution rates.
• Pricing, rebate, and payer acceptance dynamics.
• Supply and tender economics in pediatric procurement cycles.

No market baseline, pricing terms, uptake data, or forecast assumptions are available in this chat. As a result, a data-anchored projection cannot be generated.

---

Key Takeaways

• Triumeq PD is the pediatric formulation variant of Triumeq (DTG/ABC/3TC) targeted to pediatric dosing practicality and labeling expansion.
• A complete, decision-grade update on clinical trial status, Orange Book listing status, patent/protection scope, paragraph IV risk, and launch timing requires product-specific datasets that are not present in this chat.
• Business planning for Triumeq PD should be anchored to (1) pediatric label acceptance and availability timing and (2) formulation and method-of-use patent expirations that determine generic substitution eligibility.

FAQs

1. What clinical trial endpoints are most important for pediatric Triumeq PD dosing approval?
2. How do formulation patents for pediatric fixed-dose combinations typically limit generic substitution?
3. Which FDA labeling elements for pediatric HIV regimens most affect payer adoption?
4. What settlement terms most influence generic launch timing for ANDA paragraph IV cases?
5. How does weight-band dosing design impact real-world adherence in pediatric HIV?

References

No sources were provided in the chat to cite.